Heron Therapeutics (NASDAQ:HRTX) Announces Earnings Results

Heron Therapeutics (NASDAQ:HRTX) released its quarterly earnings results on Monday. The biotechnology company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03), FiscalAI reports. Heron Therapeutics had a negative return on equity of 277.36% and a negative net margin of 14.55%. The business had revenue of $35.25 million during the quarter, compared to analyst estimates of $37.50 million.

Heron Therapeutics Stock Performance

Shares of HRTX opened at $0.36 on Thursday. The company has a 50-day simple moving average of $0.33 and a two-hundred day simple moving average of $0.66. The company has a debt-to-equity ratio of 32.59, a current ratio of 2.33 and a quick ratio of 1.51. The firm has a market capitalization of $68.36 million, a PE ratio of -2.99 and a beta of 1.65. Heron Therapeutics has a one year low of $0.26 and a one year high of $1.57.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HRTX. Wall Street Zen raised Heron Therapeutics to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, October 15th. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, HC Wainwright downgraded shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $2.00.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.